Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition: Moderate to Severe Active Rheumatoid Arthritis Interventions: Drug: HS628+MTX; Drug: Actemra +MTX Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition: Rheumatoid Arthritis Interventions: Other: Treatment target DAS28CRP-LDA; Other: Treatment target SDAI-remission Sponsor: Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition: Moderate to Severe Active Rheumatoid Arthritis Interventions: Drug: HS628+MTX; Drug: Actemra +MTX Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition: Rheumatoid Arthritis Interventions: Other: Treatment target DAS28CRP-LDA; Other: Treatment target SDAI-remission Sponsor: Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition: Moderate to Severe Active Rheumatoid Arthritis Interventions: Drug: HS628+MTX; Drug: Actemra +MTX Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition: Rheumatoid Arthritis Interventions: Other: Treatment target DAS28CRP-LDA; Other: Treatment target SDAI-remission Sponsor: Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition: Moderate to Severe Active Rheumatoid Arthritis Interventions: Drug: HS628+MTX; Drug: Actemra +MTX Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition: Rheumatoid Arthritis Interventions: Other: Treatment target DAS28CRP-LDA; Other: Treatment target SDAI-remission Sponsor: Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
Condition: Moderate to Severe Active Rheumatoid Arthritis Interventions: Drug: HS628+MTX; Drug: Actemra +MTX Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
TrEatment Targets in Rheumatoid Arthritis: a Randomized Multi-centre, Treat to Target Strategy Trial: TETRA Study
Condition: Rheumatoid Arthritis Interventions: Other: Treatment target DAS28CRP-LDA; Other: Treatment target SDAI-remission Sponsor: Sint Maartenskliniek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (Renoir)
Condition: Rheumatoid Arthritis Interventions: Drug: ANB030; Drug: Placebo Sponsor: AnaptysBio, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials